Documents Cited in The Cancer Letter

2016 – Volume 42

  • The Blue Ribbon Panel 2016 report, presented to the National Cancer Advisory Board on Sept. 7
  • (The Cancer Letter, September 2, 2016)
  • The full list of recent recruitments and promotions at Roswell Park Cancer Institute (The Cancer Letter, May 27, 2016).
  • The open letter , signed by 150 organizations, to the Senate HELP committee on medical innovations legislation (The Cancer Letter, April 29, 2016).
  • Fitzpatrick Letters: FDA’s letter on inspections of hospitals on adverse outcomes reporting, and Rep. Mike Fitzpatrick’s (R-Pa.) letter to Vice President Joe Biden on medical device safety regulations, the Cancer Moonshot and the FDA Oncology Center of Excellence (The Cancer Letter, April 15, 2016).
  • The FDA's order granting PneumoLiner Class II device classification (The Cancer Letter, April 8, 2016).
  • Amy Reed’s consent form for her power morcellation procedure at Brigham and Women’s Hospital (The Cancer Letter, April 8, 2016).
  • Court documents regarding suits against AVEO Pharmaceuticals (Slamming the Door, March 11, 2016).
  • The Centers of Medicare and Medicaid Services’ transmittal describing its experiment that would alter ASP payment based on ZIP code, and a letter from oncology groups opposing the experiment (The Cancer Letter, March 4, 2016).
  • Fact sheet and other documents about Patrick Soon-Shiong’s Cancer MoonShot 2020 Program (The Cancer Letter, Jan. 15, 2016).

2015 – Volume 4

2014 – Volume 40

  • A May 2014 version of a patient consent form for a Brigham & Women’s Hospital study to assess leakage when using containment bags with power morcellators (The Cancer Letter, Nov. 21, 2014).
  • The statements and letters from Senators to FDA on power morcellation (The Cancer Letter, Nov. 21, 2014).
  • The data tables of NCI and NIH funding for 17 institutions from 2003 to 2013 (The Cancer Letter, Oct. 31, 2014).
  • The complaint and settlement agreement in the case filed against Charles Bennett (The Cancer Letter, Oct. 31, 2014).
  • The complaint filed by Pharmaceutical Research and Manufacturers of America against HHS and HRSA (The Cancer Letter, Oct. 24, 2014).
  • The review committee's report recommending the closing of the Indiana University Health Proton Therapy Center (The Cancer Letter, Oct. 17, 2014).
  • The Pharmaceutical Research and Manufacturers of America’s (PhRMA) lawsuit against the Department of Health & Human Services/Health Resources and Services Administration for its 340B “interpretive” rule on the Affordable Care Act orphan drug exclusion (The Cancer Letter, Oct. 10, 2014).
  • The legal files regarding the DOJ prosecutions of those involved with the supply chain moving counterfeit Avastin into the United States (The Cancer Letter, Oct. 3, 2014).
  • The April 2006 letter sent from William McGivney to Genentech CEO Art Levinson (The Cancer Letter, Oct. 3, 2014).
  • The full confidential document detailing a plan for MD Anderson’s nationwide expansion (The Cancer Letter, Sept. 26, 2014).
  • The back-and-forth correspondence between MD Anderson and the American Association of University Professors (The Cancer Letter, Sept. 19, 2014).
  • The letter from Sens. Chuck Schumer and Kirsten Gillibrand to FDA Commissioner Margaret Hamburg regarding power morcellation (The Cancer Letter, Aug. 27, 2014).
  • The Appendix in Support and the answer to the second amended complaint in the case against Caris Life Sciences (The Cancer Letter, Aug. 8, 2014)
  • AAGL spokesperson Jubilee Brown’s presentation slides and remarks July 11 to the FDA Obstetrics and Gynecology Devices Panel on power morcellation (The Cancer Letter, July 25, 2014).
  • MD Anderson Faculty Senate's recommendations to the DePinho administration, Boyd’s July 10 letter to AAUP, and Powis's letters to the administration regarding Kapil Mehta (The Cancer Letter, July 18, 2014).
  • PhRMA’s complaint regarding 340B, Judge Contreras’s ruling, and the DOJ’s response (The Cancer Letter, June 13, 2014).
  • Hope Cancer Institute $2.9 million settlement agreement and complaint in Medicare overbilling allegations (The Cancer Letter, June 6, 2014).
  • Letters of support for Kapil Mehta’s tenure renewal at MD Anderson (The Cancer Letter, May 30, 2014).
  • Zhengxin Wang’s denial of appeal and his complaint to the EEOC (The Cancer Letter, May 30, 2014).
  • MD Anderson’s policy for faculty appeals (The Cancer Letter, May 30, 2014).
  • The MD Anderson 2012 and 2014 BIG Survey results, and 835 pages of comments by MD Anderson employees (The Cancer Letter, May 23, 2014).
  • The AAUP’s 1940 and 1958 statements on tenure and faculty dismissal, and its 2013 recommended regulations (The Cancer Letter, May 16, 2014).
  • Douglas Boyd’s supporting documents sent to AAUP, making the case for an investigation into MD Anderson’s decision to deny tenure to two faculty members (The Cancer Letter, May 16, 2014).
  • Peter Bach’s presentation to the CMS advisory committee on LCA’s certification process (The Cancer Letter, May 9, 2014).
  • A recording of NCI's conference call with patient advocates regarding NCTN (The Cancer Letter, May 2, 2014).
  • The MD Anderson Faculty Senate report on renewal of tenure and “the presidential veto” (The Cancer Letter, April 25, 2014).
  • Kapil Mehta’s timeline of events and related documents as he sought renewal of his tenure at MD Anderson (The Cancer Letter, April 25, 2014).
  • Zhengxin Wang’s timeline of events and related documents as he sought to renew his tenure at MD Anderson (The Cancer Letter, April 25, 2014).
  • The letter sent to investigators March 6, detailing NCI’s plans for phasing out CCOP and the transition to NCORP (The Cancer Letter, April 11, 2014).
  • The May 13 and June 24, 1994 issues of The Cancer Letter, covering Bernard Fisher’s removal from the NSABP (The Cancer Letter, April 4, 2014).
  • The presentations made by David Heimbrook and Robert Wiltrout regarding the Frederick National Lab (The Cancer Letter, Feb. 28, 2014).
  • The white paper produced by GOG regarding NCI CTEP supported gynecologic cancer research trials (The Cancer Letter, Feb. 21, 2014).
  • The full confidential document detailing a plan for MD Anderson’s nationwide expansion (The Cancer Letter, Feb. 7, 2014).
  • The Cancer Letter’s Conversation with Peter Boyle, president of IPRI (The Cancer Letter, Jan. 31, 2014).
  • The Cancer Letter’s Conversation with John Seffrin, retiring CEO of the American Cancer Society (The Cancer Letter, Jan. 24, 2014).
  • The Cancer Letter’s Conversation with Mark Roh, president of Orlando Health Center (The Cancer Letter, Jan. 10, 2014).

2013 Volume 39

2012 Volume 38

  • William Gimson’s resignation letter, from the Cancer Prevention & Research Institute of Texas (The Cancer Letter, Dec. 14, 2012).
  • Confirmation of an inquiry by the Texas Office of the Attorney General into CPRIT’s funding of Peloton Therapeutics (The Cancer Letter, Dec. 14, 2012).
  • The letter from CPRIT’s founding legislators expressing concern to CPRIT’s investigators (The Cancer Letter, Dec. 14, 2012).
  • The letter from the Travis County District Attorney to Kristen Doyle, CPRIT’s general counsel (The Cancer Letter, Dec. 14, 2012).
  • CPRIT’s announcement of the appointment of Margaret Kripke as chief scientific officer (The Cancer Letter, Dec. 14, 2012).
  • An audio recording of Kripke’s telephone conference with reporters (The Cancer Letter, Dec. 14, 2012).
  • A letter from Richard Schilsky to his colleagues at the University of Chicago.
  • The American Society of Clinical Oncology’s press release announcing Richard Schilsky being named chief medical officer.
  • University of Chicago’s notice to faculty announcing Richard Schilsky being named chief medical officer of the American Society for Clinical Oncology.
  • MD Anderson’s August 2012 Financials (The Cancer Letter, Oct. 12, 2012).
  • A recording of MD Anderson President Ronald DePinho’s State of the Institution speech (The Cancer Letter, Oct. 12, 2012).
  • The CPRIT Email Archive obtained by The Cancer Letter detailing the agency’s reaction to MD Anderson’s incubator proposal (The Cancer Letter, Sept. 28, 2012).
  • UT System documents pertaining to the hiring of DePinho and Chin (The Cancer Letter, Sept. 21, 2012).
  • MD Anderson Moon Shots Program Backgrounder (The Cancer Letter, Sept. 21, 2012).
  • MSP: Breast and Ovarian Cancer Backgrounder (The Cancer Letter, Sept. 21, 2012).
  • MSP: CLL Backgrounder (The Cancer Letter, Sept. 21, 2012).
  • MSP: Melanoma Backgrounder (The Cancer Letter, Sept. 21, 2012).
  • MSP: AML MDS Backgrounder (The Cancer Letter, Sept. 21, 2012).
  • MSP: Lung Cancer Backgrounder (The Cancer Letter, Sept. 21, 2012).
  • Robert DePinho’s letter to Rep. Fred Upton (The Cancer Letter, Sept. 14, 2012).
  • AAMC’s letter to Sen. Sheldon Whitehouse (The Cancer Letter, Sept. 14, 2012).
  • AACR’s letter to Sen. Sheldon Whitehouse (The Cancer Letter, Sept. 14, 2012).
  • PANCan’s Letter to Reps. Anna Eshoo and Leonard Lance (The Cancer Letter, Sept. 14, 2012).
  • CLS’s letter to Rep. Fred Upton (The Cancer Letter, Sept. 14, 2012).
  • Pancreatic Cancer Action Network’s advocacy materials packet including fact sheets for policymakers (The Cancer Letter, Aug. 3, 2012).
  • A document describing how N-CORP will be divided into levels 1, 2 and 3 (The Cancer Letter, July 13, 2012).
  • The MD Anderson-CPRIT Compliance Review Report (The Cancer Letter, June 15, 2012).
  • A transcript of MD Anderson President Ronald DePinho’s appearance on CNBC (The Cancer Letter, June 1, 2012).
  • The MD Anderson IACS six-and-a-half-page-long grant application (The Cancer Letter, May 25, 2012).
  • The appendix to the IACS grant application, including budgets (The Cancer Letter, May 25, 2012).
  • Ronald DePinho’s remarks to the Board of Visitors in October 2011 (The Cancer Letter, May 25, 2012).
  • The NCI Memo circulated before the cancer center directors’ April 19 retreat (The Cancer Letter, May 11, 2012).
  • An outline of the 2013 CCSG Guideline Changes (The Cancer Letter, May 11, 2012).
  • A draft of the 2013 CCSG Guidelines (The Cancer Letter, May 11, 2012).
  • A summary of the 2013 CCSG Guideline Changes (The Cancer Letter, May 11, 2012).
  • Director Cullen’s letter to NCI's Weiss (The Cancer Letter, May 11, 2012).
  • The letter sent by 11 cancer center directors to Weiss (The Cancer Letter, May 11, 2012).
  • The Opposition to Seal, sent by attorneys representing Amelia Weber (The Cancer Letter, April 20, 2012).
  • Urorad Healthcare’s FAQ sheet regarding developing IMRT centers (The Cancer Letter, April 13, 2012).
  • TwinCrest Group’s flyer to urology practices offering in-office pathology (The Cancer Letter, April 13, 2012).
  • Part one of a collection of files containing Craig Thompson’s Motion to Dismiss, filed as part of the Abramson lawsuit (The Cancer Letter, March 23, 2012).
  • Part two of a collection of files containing Thompson’s Motion to Dismiss (The Cancer Letter, March 23, 2012).
  • Agios Pharmaceuticals’ Motion to Dismiss, filed against Abramson lawsuit (The Cancer Letter, March 23, 2012).
  • UPenn’s complaint against former cancer center director, Craig Thompson (The Cancer Letter, March 9, 2012).
  • Attachments to UPenn’s complaint (The Cancer Letter, March 9, 2012).
  • The Abramson Institute’s complaint against former cancer center director, Craig Thompson (The Cancer Letter, March 9, 2012).
  • The Susan G. Komen Foundation 2010 Affiliation Policies document (The Cancer Letter, Feb. 3, 2012).
  • The Susan G. Komen Foundation 2010 Affiliation Agreement document (The Cancer Letter, Feb. 3, 2012).
  • FDA’s letter to the Division of Medical Oncology, Duke University Medical Center (The Cancer Letter, Jan. 27, 2012).
  • Letter to CDER from the Duke University Medical Center (The Cancer Letter, Jan. 27, 2012).
  • FDA Establishment Inspection Report, January 2011 (The Cancer Letter, Jan. 27, 2012).
  • NVCI co-founder Heather Murren’s declaration in bankruptcy court (The Cancer Letter, Jan. 20, 2012).
  • Restructuring consultant George Pillari’s declaration in NVCI’s bankruptcy court (The Cancer Letter, Jan. 20, 2012).
  • The Cancer Letter’s interview with Robert Young, former NCCN chairman: Part 1 and Part 2 (The Cancer Letter, Jan. 13, 2012).
  • The Cancer Letter’s interview with Catherine Harvey, NCCN’s first executive director: Part 1 and part 2 (The Cancer Letter, Jan. 13, 2012).
  • The March 15, 1996,, and Jan. 24, 1997, issues of The Cancer Letter (The Cancer Letter, Jan. 13, 2012).

2011 Volume 37

2010 Volume 36

  • NIH response to Sen. Charles Grassley on sponsored travel by NCI scientists (The Cancer Letter, Dec. 3, 2010).
  • NCI-funded CISNET model presented by Harvard researchers predicting outcome of National Lung Screening Trial (The Cancer Letter, Nov. 26, 2010).
  • Sen. Charles Grassley letter to NIH Director Francis Collins and NCI Director Harold Varmus on “sponsored travel” by NCI scientists (The Cancer Letter, Oct. 29, 2010.)
  • NCI letter of Oct. 15, 2010 on carboplatin dosing, referenced in The Cancer Letter, Oct. 22, 2010.
  • NCI letter of Oct. 1, 2010, “Action Letter for Protocols Sponsored by the National Cancer Institute That Use Carboplatin.” Referenced in The Cancer Letter, Oct. 8, 2010.
  • Documents on Avastin referenced in Sept. 3, 2010, issue of The Cancer Letter: Howard Burris letter; AdvancedBC.org letter; advocacy groups’ letter to FDA; Kathy Miller letter to ES103 investigators; Gabriel Hortobagyi email; National Breast Cancer Coalition letter to FDA.
  • The Potti Scandal documents mentioned in The Cancer Letter, July 30, 2010: Potti's bio submitted to Department of Defense.
  • The Potti Scandal documents mentioned in The Cancer Letter, July 23, 2010: Letter by 33 biostatisticians to NCI Director Harold Varmus. Letter by American Cancer Society Chief Medical Officer Otis Brawley to Duke University. A list of Potti’s technologies available for licensing from Duke. More detailed description of one of these technologies.
  • Duke scientist Anil Potti’s different CVs: version 1, version 2, and version 3. His University of North Dakota Residency application, and a page from a Duke brochure listing his claimed Rhodes scholarship. The Cancer Letter, July 16, 2010.
  • City of Hope dispute with for-profit physician group reading materials (.zip file), referenced in The Cancer Letter, May 28, 2010.
  • Entertainment Industry Foundation’s 2008 IRS Form 900, referenced in The Cancer Letter, May 21, 2010.
  • Documents on Duke University genomics research: Duke report and email obtained by The Cancer Letter; comments by biostatisticians on the report (The Cancer Letter, May 14, 2010).
  • Letters by American Society of Clinical Oncology and the Massachusetts Hospital Association protesting Mass. Blues restrictions on ESAs (The Cancer Letter, April 9. 2010).
  • Analysis of industry-sponsored phase I studies prepared by The Cancer Letter for article in March 26, 2010, issue.
  • NCI concept statements: Barrett's Esophagus Translational Research Network and Commercial Application and Use of Emerging Molecular Analysis Technologies (SBIR) (The Cancer Letter, March 19, 2010).
  • NCI concept statement: Clinical Proteomic Technologies for Cancer (The Cancer Letter, March 12, 2010).
  • Documents (zip file) in Allergan lawsuit against FDA over off-label use promotion (The Cancer Letter, Jan. 15, 2010).